MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Contineum Therapeutics, Inc. - Common stock (NQ:CTNM)

15.10 -0.14 (-0.92%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 378,661
Open 15.44
Bid (Size) 6.040 (200)
Ask (Size) 24.14 (200)
Prev. Close 15.24
Today's Range 14.71 - 15.88
52wk Range 3.720 - 16.91
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference
From Contineum Therapeutics, Inc.
Via Business Wire

Performance

YTD
+32.6%
+32.6%
1 Month
+22.4%
+22.4%
3 Month
+12.4%
+12.4%
6 Month
+51.0%
+51.0%
1 Year
+296.3%
+296.3%

More News

Read More
News headline image
Contineum Therapeutics Touts PIPE-791 IPF Focus as Pain Data Hint at Wider Potential ↗
Via MarketBeat
Contineum Therapeutics (NASDAQ:CTNM) Reports Q4 2025 Loss, Highlights Clinical Progress and Extended Cash Runway ↗
Via Chartmill
News headline image
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Announces Proposed $75.0 Million Public Offering
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference
From Contineum Therapeutics
Via Business Wire
News headline image
Get insights into the top gainers and losers of Thursday's after-hours session. ↗
Via Chartmill
News headline image
Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
This Lululemon Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday ↗
Via Benzinga
News headline image
This Biogen Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Via Benzinga
News headline image
Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
From Contineum Therapeutics, Inc.
Via Business Wire

Frequently Asked Questions

Is Contineum Therapeutics, Inc. - Common stock publicly traded?
Yes, Contineum Therapeutics, Inc. - Common stock is publicly traded.
What exchange does Contineum Therapeutics, Inc. - Common stock trade on?
Contineum Therapeutics, Inc. - Common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Contineum Therapeutics, Inc. - Common stock?
The ticker symbol for Contineum Therapeutics, Inc. - Common stock is CTNM on the Nasdaq Stock Market
What is the current price of Contineum Therapeutics, Inc. - Common stock?
The current price of Contineum Therapeutics, Inc. - Common stock is 15.10
When was Contineum Therapeutics, Inc. - Common stock last traded?
The last trade of Contineum Therapeutics, Inc. - Common stock was at 07/02/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story